Evidence map›Paper›PMID 30421178›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial.

N Kouhi Habibi, A Shabestani Monfared, K Ebrahimnejad Gorji, M Karimi, A A Moghadamnia, M Tourani, S Borzoueisileh, F Niksirat

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

N Kouhi HabibiStudent Research Committee, Babol University of Medical Sciences, Babol, Iran.
A Shabestani MonfaredCancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. monfared_ali@yahoo.com.ORCID http://orcid.org/0000-0002-1457-7199
K Ebrahimnejad GorjiDepartment of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
M KarimiCancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
A A MoghadamniaDepartment of Pharmacology, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
M TouraniCellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
S BorzoueisilehStudent Research Committee, Babol University of Medical Sciences, Babol, Iran.
F NiksiratCancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Babol University of Medical Sciences · IR

Funding

Babol University of Medical Sciences 2900
6 · The paper itself

Abstract

purposeWe aimed to examine the radioprotective effects of melatonin on the blood cell counts of patients with rectum cancer undergoing radiotherapy. MATERIALS AND

methodsThis double-blind placebo-controlled study was conducted on 60 rectal cancer patients who were referred to Rajaii Hospital of Babolsar, Iran. An equal number of patients were randomly assigned to the control group which received placebo and study group which received 20 mg melatonin a day as an intervention. The melatonin was administered 5 days a week for 28 days. Blood samples were taken before melatonin received on day 1 and also day 28; then, to measure the changes in blood cell counts representing our primary outcomes, the samples were analyzed by Sysmex K810i auto-analyzer.

resultsOur results showed that the platelet, white blood cells, lymphocyte, and neutrophil population reduction induced by radiotherapy were slighter or even insignificant in melatonin recipients compared to control. However, the difference between red blood cells in both groups was not significant.

conclusionOur results are indicating that melatonin could prevent or minimize the unfavorable effects of radiotherapy on blood cell count reductions by attenuating the adverse influence of radiation, probably through stimulation of cellular antioxidant potential as previously reported in animal models. IRANIAN REGISTRY OF CLINICAL TRIALS (IRCT): Registry No. IRCT2016021626586N1.

Indexed as

ChemoradiotherapyAdultAgedAntioxidantsBlood Cell CountDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMelatoninMiddle AgedPrognosisProtective AgentsRectal NeoplasmsAntioxidantsMelatoninProtective AgentsBlood cellsMelatoninRadiotherapyRectal cancer

Identifiers

PMID30421178
OpenAlexW2900937811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.